Hoth Therapeutics reports positive drug trial data

Hoth Therapeutics has announced encouraging results from its Phase 1 trial for HT-001, a treatment for skin toxicities associated with cancer therapy. The data indicates a substantial increase in drug exposure, approximately 77%, with minimal systemic side effects observed. These positive pharmacokinetic and safety findings suggest HT-001 holds promise for improving patient outcomes and managing a common, debilitating side effect of EGFR-targeted cancer treatments.